23andMe (ME) Stock Forecast, Price Target & Predictions
ME Stock Forecast
23andMe stock forecast is as follows: an average price target of $3.71 (represents a -24.44% downside from ME’s last price of $4.91) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ME Price Target
The average price target for 23andMe (ME) is $3.71 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $0.42. This represents a potential -24.44% downside from ME's last price of $4.91.
ME Analyst Ratings
According to 2 Wall Street analysts, 23andMe's rating consensus is 'Buy'. The analyst rating breakdown for ME stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
23andMe Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Daniel Grosslight | Citigroup | $0.42 | $0.34 | 23.53% | -91.45% |
| Nov 29, 2022 | - | Berenberg Bank | $7.00 | $2.76 | 153.62% | 42.57% |
The latest 23andMe stock forecast, released on Sep 16, 2024 by Daniel Grosslight from Citigroup, set a price target of $0.42, which represents a 23.53% increase from the stock price at the time of the forecast ($0.34), and a -91.45% decrease from ME last price ($4.91).
23andMe Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $0.42 | $0.42 |
| Last Closing Price | $4.91 | $4.91 | $4.91 |
| Upside/Downside | -100.00% | -91.45% | -91.45% |
In the current month, the average price target of 23andMe stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 23andMe's last price of $4.91. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 28, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 15, 2024 | Citigroup | Neutral | Neutral | Hold |
23andMe's last stock rating was published by Citigroup on Sep 16, 2024. The company gave ME a "Neutral" rating, the same as its previous rate.
23andMe Financial Forecast
23andMe Revenue Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $44.75M | $50.00M | $60.86M | $92.38M | $66.94M | $75.66M | $64.51M | $100.56M | $56.89M | $55.20M |
| Avg Forecast | $48.76M | $41.10M | $36.41M | $53.80M | $55.82M | $54.03M | $56.80M | $56.90M | $88.40M | $65.90M | $63.54M | $61.60M | $102.79M | $54.30M | $55.71M |
| High Forecast | $48.76M | $41.10M | $36.41M | $53.80M | $55.82M | $54.03M | $56.80M | $56.90M | $88.40M | $65.90M | $63.54M | $61.60M | $102.79M | $54.30M | $55.71M |
| Low Forecast | $48.76M | $41.10M | $36.41M | $53.80M | $55.82M | $54.03M | $56.80M | $56.90M | $88.40M | $65.90M | $63.54M | $61.60M | $102.79M | $54.30M | $55.71M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | 0.83% | 0.88% | 1.07% | 1.04% | 1.02% | 1.19% | 1.05% | 0.98% | 1.05% | 0.99% |
23andMe's average Quarter revenue forecast for Mar 24 based on 1 analysts is $55.82M, with a low forecast of $55.82M, and a high forecast of $55.82M. ME's average Quarter revenue forecast represents a 24.75% increase compared to the company's last Quarter revenue of $44.75M (Dec 23).
23andMe EBITDA Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | $126.70M | $-65.71M | $-109.26M | $-60.91M | $-97.10M | $-58.63M | $-80.18M | $-69.45M | $-85.33M | $-11.65M |
| Avg Forecast | $-39.72M | $-33.48M | $-29.66M | $-43.83M | $-45.48M | $-44.02M | $-46.27M | $-46.36M | $-72.02M | $-53.69M | $-51.76M | $-50.18M | $-62.84M | $-44.24M | $-45.39M |
| High Forecast | $-39.72M | $-33.48M | $-29.66M | $-43.83M | $-45.48M | $-44.02M | $-46.27M | $-46.36M | $-72.02M | $-53.69M | $-51.76M | $-50.18M | $-50.27M | $-44.24M | $-45.39M |
| Low Forecast | $-39.72M | $-33.48M | $-29.66M | $-43.83M | $-45.48M | $-44.02M | $-46.27M | $-46.36M | $-72.02M | $-53.69M | $-51.76M | $-50.18M | $-75.40M | $-44.24M | $-45.39M |
| Surprise % | - | - | - | - | - | -2.88% | 1.42% | 2.36% | 0.85% | 1.81% | 1.13% | 1.60% | 1.11% | 1.93% | 0.26% |
1 analysts predict ME's average Quarter EBITDA for Mar 24 to be $-45.48M, with a high of $-45.48M and a low of $-45.48M. This is -135.89% lower than 23andMe's previous annual EBITDA (Dec 23) of $126.70M.
23andMe Net Income Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | $-277.98M | $-75.27M | $-104.62M | $-64.10M | $-91.96M | $-66.06M | $-89.53M | $-69.54M | $-89.40M | $13.40M |
| Avg Forecast | $-1.21B | $-1.58B | $-1.56B | $-2.18B | $-1.65B | $-1.39B | $-1.39B | $-1.48B | $-1.57B | $-1.89B | $-1.69B | $-1.59B | $-69.54M | $-1.56B | $-1.26B |
| High Forecast | $-1.21B | $-1.58B | $-1.56B | $-2.18B | $-1.65B | $-1.39B | $-1.09B | $-1.48B | $-1.57B | $-1.89B | $-1.69B | $-1.59B | $-55.64M | $-1.56B | $-1.26B |
| Low Forecast | $-1.21B | $-1.58B | $-1.56B | $-2.18B | $-1.65B | $-1.39B | $-1.69B | $-1.48B | $-1.57B | $-1.89B | $-1.69B | $-1.59B | $-83.45M | $-1.56B | $-1.26B |
| Surprise % | - | - | - | - | - | 0.20% | 0.05% | 0.07% | 0.04% | 0.05% | 0.04% | 0.06% | 1.00% | 0.06% | -0.01% |
23andMe's average Quarter net income forecast for Dec 21 is $-1.56B, with a range of $-1.56B to $-1.56B. ME's average Quarter net income forecast represents a -11751.50% decrease compared to the company's last Quarter net income of $13.40M (Sep 21).
23andMe SG&A Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | $57.18M | $40.98M | $73.40M | $48.54M | $70.58M | $50.45M | $63.08M | $66.19M | $71.43M | $29.85M |
| Avg Forecast | $35.45M | $29.88M | $26.47M | $39.12M | $40.59M | $39.28M | $41.30M | $41.37M | $64.27M | $47.91M | $46.20M | $44.79M | $66.19M | $39.48M | $40.51M |
| High Forecast | $35.45M | $29.88M | $26.47M | $39.12M | $40.59M | $39.28M | $41.30M | $41.37M | $64.27M | $47.91M | $46.20M | $44.79M | $79.42M | $39.48M | $40.51M |
| Low Forecast | $35.45M | $29.88M | $26.47M | $39.12M | $40.59M | $39.28M | $41.30M | $41.37M | $64.27M | $47.91M | $46.20M | $44.79M | $52.95M | $39.48M | $40.51M |
| Surprise % | - | - | - | - | - | 1.46% | 0.99% | 1.77% | 0.76% | 1.47% | 1.09% | 1.41% | 1.00% | 1.81% | 0.74% |
23andMe's average Quarter SG&A projection for Mar 24 is $40.59M, based on 1 Wall Street analysts, with a range of $40.59M to $40.59M. The forecast indicates a -29.02% fall compared to ME last annual SG&A of $57.18M (Dec 23).
23andMe EPS Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | $-0.58 | $-0.16 | $-0.23 | $-0.14 | $-0.20 | $-0.15 | $-0.20 | $-0.16 | $-0.21 | $0.03 |
| Avg Forecast | $-2.43 | $-3.19 | $-3.15 | $-4.40 | $-3.32 | $-2.80 | $-2.81 | $-2.99 | $-3.18 | $-3.81 | $-3.41 | $-3.21 | $-2.54 | $-3.15 | $-2.53 |
| High Forecast | $-2.43 | $-3.19 | $-3.15 | $-4.40 | $-3.32 | $-2.80 | $-2.21 | $-2.99 | $-3.18 | $-3.81 | $-3.41 | $-3.21 | $-2.54 | $-3.15 | $-2.53 |
| Low Forecast | $-2.43 | $-3.19 | $-3.15 | $-4.40 | $-3.32 | $-2.80 | $-3.41 | $-2.99 | $-3.18 | $-3.81 | $-3.41 | $-3.21 | $-2.54 | $-3.15 | $-2.53 |
| Surprise % | - | - | - | - | - | 0.21% | 0.06% | 0.08% | 0.04% | 0.05% | 0.04% | 0.06% | 0.06% | 0.07% | -0.01% |
According to 1 Wall Street analysts, 23andMe's projected average Quarter EPS for Dec 21 is $-3.15, with a low estimate of $-3.15 and a high estimate of $-3.15. This represents a -9669.09% decrease compared to ME previous annual EPS of $0.03 (Sep 21).
23andMe Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DMTK | DermTech | $0.09 | $15.00 | 16566.67% | Buy |
| GH | Guardant Health | $20.68 | $57.27 | 176.93% | Buy |
| ILMN | Illumina | $143.52 | $199.67 | 39.12% | Buy |
| DHR | Danaher | $271.98 | $313.67 | 15.33% | Buy |
| A | Agilent | $137.42 | $152.64 | 11.08% | Buy |
| TMO | Thermo Fisher Scientific | $599.25 | $642.48 | 7.21% | Buy |
| IDXX | IDEXX Laboratories | $460.01 | $479.75 | 4.29% | Buy |
| WAT | Waters | $347.31 | $356.80 | 2.73% | Buy |
| TWST | Twist Bioscience | $45.52 | $42.40 | -6.85% | Buy |
| ME | 23andMe | $4.91 | $3.71 | -24.44% | Buy |
| HTGM | HTG Molecular Diagnostics | $0.48 | $0.17 | -64.58% | Buy |
ME Forecast FAQ
Is 23andMe a good buy?
Yes, according to 2 Wall Street analysts, 23andMe (ME) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of ME's total ratings.
What is ME's price target?
23andMe (ME) average price target is $3.71 with a range of $0.42 to $7, implying a -24.44% from its last price of $4.91. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will 23andMe stock go up soon?
According to Wall Street analysts' prediction for ME stock, the company can go down by -24.44% (from the last price of $4.91 to the average price target of $3.71), up by 42.57% based on the highest stock price target, and down by -91.45% based on the lowest stock price target.
Can 23andMe stock reach $7?
ME's average twelve months analyst stock price target of $3.71 does not support the claim that 23andMe can reach $7 in the near future.
What are 23andMe's analysts' financial forecasts?
23andMe's analysts financial forecasts for the fiscal year (Mar 2024) are as follows: average revenue is $223.55M (high $223.55M, low $223.55M), average EBITDA is $-182M (high $-182M, low $-182M), average net income is $-5.911B (high $-5.613B, low $-6.21B), average SG&A $162.54M (high $162.54M, low $162.54M), and average EPS is $-11.92 (high $-11.318, low $-12.523). ME's analysts financial forecasts for the fiscal year (Mar 2025) are as follows: average revenue is $180.07M (high $180.07M, low $180.07M), average EBITDA is $-147M (high $-147M, low $-147M), average net income is $-6.529B (high $-6.529B, low $-6.529B), average SG&A $130.92M (high $130.92M, low $130.92M), and average EPS is $-13.166 (high $-13.166, low $-13.166).
Did the ME's actual financial results beat the analysts' financial forecasts?
Based on 23andMe's last annual report (Mar 2023), the company's revenue was $299.49M, beating the average analysts forecast of $279.44M by 7.18%. Apple's EBITDA was $-288M, beating the average prediction of $-228M by 26.30%. The company's net income was $-312M, missing the average estimation of $-6.745B by -95.38%. Apple's SG&A was $235.91M, beating the average forecast of $203.17M by 16.12%. Lastly, the company's EPS was $-0.69, missing the average prediction of $-13.602 by -94.93%. In terms of the last quarterly report (Dec 2023), 23andMe's revenue was $44.75M, missing the average analysts' forecast of $54.03M by -17.18%. The company's EBITDA was $126.7M, missing the average prediction of $-44.018M by -387.84%. 23andMe's net income was $-278M, missing the average estimation of $-1.387B by -79.96%. The company's SG&A was $57.18M, beating the average forecast of $39.28M by 45.56%. Lastly, the company's EPS was $-0.58, missing the average prediction of $-2.797 by -79.27%